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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is the second-leading cause of death in the United Kingdom and
accounts for 1.7% of bed days in acute hospitals. An estimated two-third of patients with COPD remain undiagnosed.
Objective: Modern Innovative Solutions in Improving Outcomes in Chronic Obstructive Pulmonary Disease (MISSION COPD)
aimed to proactively identify patients from primary care who were undiagnosed or had uncontrolled COPD and to provide a
comprehensive integrated multidisciplinary clinic to address the needs of this complex group for improving diagnosis, personalizing
therapy, and empowering patients to self-manage their condition.
Methods: This clinic was led by a respiratory specialist team from Portsmouth Hospitals NHS Trust working with five primary
care surgeries in Wessex. A total of 108 patients were reviewed, with 98 patients consenting to provide additional data for research.
Diagnoses were changed in 14 patients, and 32 new diagnoses were made.
Results: Reductions were seen across all aspects of unscheduled care as compared to the prior 12 months, including in emergency
general practitioner visits (3.37-0.79 visits per patient, P<.001), exacerbations (2.64-0.56 per patient, P=.01), out-of-hours calls
(0.16-0.05 per patient, P=.42), and hospital admissions (0.49-0.12 per patient, P=.48). Improvements were observed in the quality
of life and symptom scores in addition to patient activation and patient-reported confidence levels.
Conclusions: This pilot demonstrates that the MISSION model may be an effective way to provide comprehensive gold-standard
care that is valued by patients and to promote integration across sectors.
(Interact J Med Res 2019;8(4):e9637)  doi: 10.2196/ijmr.9637
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Introduction
Over 1 million people in the United Kingdom suffer from
chronic obstructive pulmonary disease (COPD), which remains
the second-leading cause of death in the United Kingdom. These
people place a significant burden on the National Health Service
through urgent unscheduled care visits in primary and secondary
care. However, there are a significant number of patients who
remain undiagnosed despite the presence of symptoms or risk
factors that are often not recognized, and the opportunity to
diagnose COPD is often missed [1]. In people who are
diagnosed, management within primary care is led by nursing
staff and is protocol driven with Quality Outcomes Framework
prompts [2], resulting in yearly reviews that are largely disease
focused. This approach risks underidentifying comorbidities as
well as the psychological and social impacts of COPD.
Diagnosis is often challenging: One meta-analysis of a variety
of case-finding strategies reported a COPD diagnostic yield of
1.7%-30.5%, with one study finding that 37.2% of new
diagnoses were severe when using a spirometric definition [3].
A Cochrane review identified 25 randomized controlled trials
of integrated disease management interventions in COPD and
concluded that such management improved the quality of life
and reduced acute hospital admissions [4]. The review identified
over 10 important aspects (eg, education, self-management,
nutrition, exercise, and case management), but no single
integrated clinic delivered the full suite of these holistic
interventions in patients diagnosed with COPD, nor could the
authors identify a comprehensive clinic targeting undiagnosed
COPD.
We describe our experience of Modern Innovative Solutions in
Improving Outcomes in Chronic Obstructive Pulmonary Disease
(MISSION COPD), a novel model of integrated care for airways
disease built on the success of the preceding MISSION Asthma
[5] model. We aimed to proactively identify patients from
electronic primary care records with either poorly controlled
disease or those in whom history was suggestive of diagnosis
but who had until then remained undiagnosed. Each patient
underwent a streamlined series of holistic assessments (delivered
by both primary and secondary care teams) incorporating
smoking cessation advice; a medical review including a
comprehensive comorbidity screen; specialist physiological
investigations including fractional exhaled nitric oxide, an
individualized inhaler technique review, a personalized
self-management plan, and written literature to support and
encourage self-management; and a chance to participate in
research. Group education sessions were delivered on the day
of the clinic, and further sessions were delivered 3 months later.
Clinics were held during weekends to increase accessibility to
the working population. By combining both primary and
secondary expertise in the patient with a COPD pathway, true
vertical integration of care was demonstrated.
This paper describes the implementation of the MISSION COPD
pilot project and the patients who accessed the service and
summarizes the impact on both patient and health service
outcomes.
Methods
Objectives
This research study accompanied the MISSION COPD Quality
Improvement Programme. The primary objective of the research
was to assess whether the number COPD exacerbations
(prednisolone or equivalent≥30 mg for >3 days or antibiotics
for >3 days [6]) improved the condition of the MISSION
patients during the 6 months after the clinic compared with the
12 months before the clinic and to assess whether hospital
admissions changed during the 6 months after the clinic.
The secondary objectives for participants with an established
diagnosis of COPD were to assess (1) whether the number of
nonelective general practitioner (GP) visits for COPD changed
during the 6 months after the clinic; (2) the severity of COPD
in the MISSION clinics; (3) the number of COPD exacerbations
in 6 months pre-MISSION and post-MISSION; (4) the patient
activation measure (PAM) pre-MISSION and post-MISSION;
(5) the frequency and severity of comorbidities in the COPD
population; (6) COPD control using the COPD Assessment Test
(CAT) questionnaire at 3 and 6 months; (7) inhaler technique
(ie, correct technique or correct device); (8) lung function and
phenotypes of patients with COPD seen in the MISSION clinic;
(9) frequency of smoking; (10) the health economic impact of
the MISSION service; (11) the number of patients with newly
diagnosed COPD; and (12) lung function and phenotypes in
patients newly diagnosed with COPD.
Setting
Primary care–based clinics were performed between September
and November 2015. Surgeries were drawn from 4 clinical
commissioning groups’ footprints surrounding Queen Alexandra
Hospital in Portsmouth. These clinical commissioning groups’
footprints are largely from rural or semirural settings. The
surgery list sizes ranged from 6895 to 15,495 patients and the
COPD list sizes ranged from 119 to 369.
This project was approved by the Berkshire Ethics Committee
(approval number 15/NS/0085).
Identification of Invitees for Clinics
Using the Grant Readiness Assessment Strategy Prep [7] COPD
and case-finding tools, databases were searched using two sets
of criteria. Criteria for patients with a suspected COPD diagnosis
(case-finding cohort) were as follows: history of smoking;
age≥35 years; presence of ≥3 respiratory symptoms coded in
the last 24 months; prescription of an inhaler without a
respiratory diagnosis; and prescription of ≥2 steroid or antibiotic
courses in the prior 2 years for a chest complaint. Patients with
an established COPD diagnosis but with uncontrolled COPD
were defined as those having (1) moderate or higher Global
Initiative for COPD stage; (2) body mass index<21 kg/m2; and
(3) ≥2 contacts with the emergency department (ED) or
out-of-hours services or ≥2 steroid courses in the prior 2 years.
Referrals were also accepted from either cohort from the
patient’s GP or practice nurse. We did not invite patients under
active secondary care follow-up (defined as a visit for the same
presentation within 6 months), but accepted patients previously
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known to receive secondary care and had been discharged. We
also excluded patients who were housebound or had significant
cognitive impairment, as the clinic structure was deemed
unsuitable.
Research Recruitment
All patients selected for clinic attendance were eligible to
participate in the study if they were able to give informed
consent. Patients were defined as being in a “care” cohort when
a diagnosis of COPD was already known and in a “case-finding”
cohort when a diagnosis was suspected.
Modern Innovative Solutions in Improving Outcomes
in Chronic Obstructive Pulmonary Disease Clinic
All participants were invited to a rapid COPD assessment clinic
(RCAC) held within primary care. This carousel clinic
encompassed targeted comorbidity screening questionnaires
such as the Hospital Anxiety and Depression Score (HADS),
Nijmegen, Epworth, Gastroesophageal Reflux Disease
Questionnaire; physiological assessment of disease severity and
phenotype (spirometry with reversibility and where appropriate,
exhaled nitric oxide); smoking cessation; inhaler technique; and
medical review. Small-group COPD education was delivered
on the day, while the clinical team held a multidisciplinary
discussion of each patient. The clinic session then ended with
individualized feedback including a self-management plan for
each participant.
Where the multidisciplinary team identified a need for further
investigation, participants were invited to a one-day severe
COPD–assessment clinic within 4 weeks of their RCAC
appointment. Each patient underwent an individualized carousel
of assessments and reviews that incorporated any number of
physiotherapies, dietetics; symptoms control, psychology, social
work, lung function laboratory assessments; echocardiographies;
and computed tomography scans. All participants ended the
clinic visit by being given further feedback and an update to
their self-management plan where needed.
Data Collection
Research participants were asked to complete clinical
assessments and questionnaires at baseline, 3 months, and 6
months.
Capturing Outcomes Related to Unscheduled Care Usage
Data related to unscheduled care usage were collected from the
primary care records (EMIS Web) for the 12 months prior to
the first clinic review and for the 6 months afterward by a
clinical fellow or experienced nurse. Unscheduled care usage
included emergency GP appointments, out-of-hours GP contact,
ED attendance, and hospital admissions where a respiratory
symptom was a driver of the episode. The number of
exacerbations was also documented, defined by a prescription
of antibiotics and steroids for chest symptoms. Unscheduled
GP visits were defined as any visit relating to the respiratory
condition that was not a planned review or scheduled follow-up
to a prior visit.
Disease Control and Severity
Baseline disease control was established using spirometry to
measure the forced vital capacity and forced expiratory volume
in 1 second, CAT [8], Medical Research Council score, St
George’s Respiratory Questionnaire (SGRQ [9]) scores, and
the Veterans Specific Activity Questionnaire scale scores.
Changes in disease control were established by further CAT
and SGRQ at 3 and 6 months.
Activation and Confidence
Patients were asked to rate their confidence in self-managing
and their knowledge of COPD on first arrival at the RCAC by
using a Likert scale. At 3 and 6 months, they were asked to rate,
on a second scale, their agreement with the statement “Attending
the MISSION COPD improved my confidence in managing my
COPD.” PAM was used to measure activation at these points.
If a person moves up one category of the PAM, it was
considered a significant increase in activation [10].
Economic Evaluation
The costs of unscheduled care usage were derived from Personal
Social Services Research Unit [11], and individuals’ use before
and after the clinic was compared. The costs of clinic delivery
were reported according to the team’s spending. Equivalent
secondary care episode costs were calculated for investigations
performed at the severe COPD clinic using current tariff rates
at the host hospital. For the case-finding cohort, an additional
preclinic cost of 3 GP visits was added as a typical diagnostic
requirement (first review visit, spirometry visit, and follow-up).
Statistical Analysis
The results were analyzed using Microsoft Excel (Microsoft
Corp, Redmond, WA) and SPSS (version 23, Armonk, NY).
The descriptive analysis of patient cohorts was guided by the
data distribution or stated as a percentage of the cohort.
Differences in unscheduled care usage were tested using
Wilcoxon signed rank tests. Validated questionnaire outcomes
were compared with the stated minimally important difference
for each questionnaire before and after data were compared for
each cohort and the total population, allowing the group to act
as its own control.
Results
Delivery of Intervention
Clinics were held from September to November 2015, and 108
patients were assessed in the clinic, with 90 patients providing
informed consent for research.
The baseline characteristics of the cohort are described in Table
1. The case cohort was younger and had fewer cumulative
pack-years of smoking history. Lung function testing and
dyspnea scores revealed greater severity of disease in the care
cohort, in keeping with the established COPD diagnosis.
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Table 1. Baseline characteristics of the clinic cohort.
Total (N=90)Case (n=32)Care (n=58)Demographics
68 (60-76)71 (64-78)64 (54-72)Age (years), median (IQRa)
42 (47)12 (52)30 (37.5)Gender (males), n (%)
Past medical history or health status
Smoking status, n (%)
30 (33)11 (33)19 (34)Current
57 (63)18 (65)39 (59)Ex-smoker
3 (4)2 (6)1 (2)Never smoker
30 (20-59)40 (20-60)23 (9-40)Smoking pack-years, mean (IQR)
28.9 (7.12)27.26 (7.26)32.2 (5.2)Body mass index (kg/m2), mean (SD)
Comorbidities, n (%)
41 (45)13 (41)28 (48)Cardiovascular
37 (41)14 (44)23 (40)Gastrointestinal or abdominal
8 (9)4 (13)4 (8)Previous nonthoracic malignancy
14 (16)7 (22)7 (12)Diabetes
Burden of comorbidity, n (%)
62 (69)18 (56)44 (76)Number of patients with >1 comorbid long-term condition
10 (11)6 (19)4 (7)Number of patients with >1 respiratory condition
Baseline disease characteristics
1.59 (1.03-2.14)1.29 (0.94-1.76)2.11 (1.72-2.63)Forced expiratory volume in 1 s (liters), mean (IQR)
59 (44-76)46 (37-65)74.5 (69-80)Forced expiratory volume in 1 s/forced vital capacity, mean (IQR)
Medicines Research Council Dyspnea Scale scores
6 (7)5 (9)1 (3)1, n (%)
11 (12)9 (15)2 (6)2, n (%)
14 (16)13 (22)1 (3)3, n (%)
7 (8)6 (10)1 (3)4, n (%)
11 (12)10 (31)1 (3)5, n (%)
411526Not defined, n
3 (2-5)3 (1-5)5 (3-7)Veterans Specific Activities Questionnaire level, mean (IQR)
aIQR: interquartile range.
Diagnoses
There were 58 patients in the care cohort where a diagnosis of
COPD was listed on EMIS and 32 patients (those with a
suspected, but as yet established COPD diagnosis) in the
case-finding cohort. Of the care cohort, 76% (44/58) remained
with a diagnosis of COPD, 14% (8/58) were rediagnosed with
asthma, 10% (6/58) had asthma-COPD overlap, and 1.7% (1/58)
had heart failure. Of the case-finding cohort, 62% (20/32) had
asthma, 9% (3/32) had COPD, 12% (4/32) had asthma-COPD
overlap, and 16% (5/32) had other diagnoses (lung cancer with
chronic hypersensitivity pneumonitis, reflux, or bronchiectasis).
Additional diagnoses of dysfunctional ventilation syndrome
were made in 40% (23/58) of the care cohort and 44% (14/32)
of the case-finding cohort using the Nijmegen questionnaire
and additional clinician assessment. In one patient in the
case-finding cohort, dysfunctional ventilation syndrome was
the primary diagnosis. A total of 22% (13/58) of care cohort
patients and 41% (13/32) of case-finding cohort patients
screened positive for anxiety and depression using HADS.
Obstructive sleep apnea was suspected in 9.8% (9/91) patients
by using Epworth Scores or clinical suspicion, of which it was
confirmed in 5 patients and disproved in 2 patients through
subsequent sleep studies; the remaining patients (n=2) did not
attend their follow-up clinic appointments.
Where additional comorbidity was suspected at the RCAC,
patients were seen in the severe COPD assessment clinic, where
access to computed tomography scanning and echocardiogram
were offered in one day in addition to palliative care review,
dietetics, and psychology assessments. These clinics found
additional diagnoses of idiopathic pulmonary fibrosis (2
patients), bronchiectasis (6 patients), respiratory bronchiolitis
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interstitial lung disease (1 patient), bronchiolitis obliterans (1
patient), lung cancer with chronic hypersensitivity pneumonitis
(1 patient), cavitatory lung disease with nontuberculous
mycobacterial infection (1 patient), significant bullous
emphysema secondary to cannabis use (1 patient), pulmonary
hypertension (5 patients), left ventricular failure (4 patients),
and valvular heart disease (1 patient).
Unscheduled Health Care Usage
The impact of attendance to the MISSION COPD clinic and
education sessions on unscheduled health care usage was
explored by capturing each individual’s usage in the 12 months
before versus 6 months after the clinic. These results show a
significant reduction in GP visits and exacerbations across both
cohorts (Table 2). Further sensitivity analyses were undertaken
to compare changes in ED attendances and hospital admissions
among those who had an episode before clinic attendance versus
annualized figures after attendance. This showed a statistically
significant reduction in ED visits (P=.01) and hospital
admissions (P=.05).
Table 2. Changes in unscheduled health care usage.
Case (n=32)Care (n=58)Total (N=90)Outcomes 12 months prior to 6 months after
clinic attendance (with figures subsequently
annualized) P valueMean per
patient af-
ter
Mean per
patient at
baseline
P valueMean per
patient af-
ter
Mean per
patient at
baseline
P valueMean per
patient af-
ter
Mean per
patient at
baseline
<.0011.53.56<.0011.413.06<.0011.43.37Unscheduled general practitioner usage
<.0011.22.78<.0010.962.42<.0011.022.64Exacerbations
.700.080.18.420.110.14.050.100.16Out-of-hours calls
.100.080.20<.00100.100.50.12Emergency department visits
.320.040.06.3300.32.180.240.49Hospital admissions
Disease-Related Quality of Life Scores
SGRQ- and CAT-validated questionnaires were used to assess
disease impact at baseline, 3 months, and 6 months. The SGRQ
was poorly filled with only 16% (16/84) of patients returning
an adequately completed series of questionnaires. Of those,
37.5% (6/16, P=.40) of the patients met the minimal clinically
significant improvement at 3 months, with 44% (7/16, P=.37)
showing improvement at 6 months. There was a significant
improvement in the CAT scores between 3 and 6 months in the
total cohort (P=.04) and in the care cohort (P=.05), but not in
the case cohort (P=.65).
Confidence and Patient Activation
Of the 87 responses to the PAM questionnaire at baseline, 11.5%
(n=13) scored 4, indicating confidence in managing problems
with their health; 34.5% (n=35) scored 3, indicating some
confidence but some inability to adapt to new challenges; 31%
(n=34) scored 2, suggesting they may lack basic knowledge
about their health; and 23% (n=22) scored 1, suggesting that
they did not know they need to play an active role in their health.
An improvement in activation according to PAM occurred in
35.7% (15/42) respondents at 3 months and 42.5% (17/40) at
6 months. A greater number of patients in the care cohort than
in the case cohort increased their activation levels at 6 months
(48% vs 33%).
Of the 70 responders at baseline, 60% (n=42) rated themselves
confident or very confident. At 3 months, 72% (21/29) of
responders and at 6 months, 86% (18/21) of responders felt the
MISSION clinic had increased their confidence.
Cost
The RCAC cost £104.39 per patient. The severe COPD
assessment clinic cost £410.81, making the total expenditure
£515.20 per patient per severe COPD clinic.
Table 3 illustrates the changes in unscheduled health care
expenditure showing a median reduction across all unscheduled
health care domains. No single measure reached statistical
significance. However, sensitivity analysis applied to cohorts
reflecting previous usage showed statistically significant
improvements in expenditure in patients with prior heavy
primary care use and those with previous hospital attendance
episodes.
Table 4 reflects the cost of the patient through the MISSION
clinic versus current care models, indicating the economic
benefit of efficiency that this streamlined model provides.
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Table 3. Cost impact of the clinics on unscheduled health care usage comparing previous 12 months with annualized 12 months (shown as expenditure
in pounds per patient).
P valuePostclinic (£), median (IQR)Preclinic (£), median (IQRa)Analysis and unscheduled care expenditure
Whole cohort (N=86)
.100 (0-145)72.50 (0-217.50)Unscheduled GPb visits
.160 (0-0)0 (0-0)Out-of-hours calls
.360 (0-0)0 (0-0)EDc attendances
.480 (0-0)0 (0-0)Hospital admissions
.010 (0-145)145 (0-362.50)Total unscheduled care expenditure
GP use cohort (n=54)
<.0010 (0-145)217.50 (145-362.50)Unscheduled GP visits
.030 (0-0)0 (0-0)Out-of-hours calls
.470 (0-0)0 (0-0)ED attendances
.710 (0-0)0 (0-0)Hospital admissions
<.0010 (0-145)217.50 (145-429.47)Total unscheduled care expenditure
Hospital use cohort (n=9)
.350 (0-145)145 (145-290)Unscheduled GP visits
.080 (0-0)0 (0-66.97)Out-of-hours calls
.010 (0-0)140.48 (140.48-140.48)ED attendances
.050 (0-0)0 (0-2249)Hospital admissions
.0080 (0-145)859.95 (647.98-2394.90)Total unscheduled care expenditure
aIQR: interquartile range.
bGP: general practitioner.
cED: emergency department.
Table 4. Costs of the patient through the Modern Innovative Solutions in Improving Outcomes in Chronic Obstructive Pulmonary Disease clinic versus
current care models.
Change in expenditure
per patient (£), mean
Equivalent cost of diagnostics
in routine care (£), mean
Cost of intervention (£),
per patient mean
Preclinic costs (£),
mean
Cohort
−98.84Not applicable104.39a286.77Care cohort - rapid clinic only
−271.19798.86544.52440.13Care cohort - rapid and severe clinic
−173.48217.50b104.39a188.31Case finding - cohort rapid only
−487.67915.47544.5272.5Case finding - cohort rapid and severe clinic
aCost of rapid assessment chronic obstructive pulmonary disease clinic.
bCost of 3 diagnostic visits to general practitioner.
Discussion
MISSION COPD is a novel model of care for patients with
airways disease, promoting vertical integration, shared
interprofessional learning, and patient education. This study
suggests that MISSION COPD improves unscheduled care
usage, patient activation, and health care costs.
This accompanying research project sought to assess the
feasibility of this project and thus was not designed to show
statistical significance. It also did not feature a control group.
We need to acknowledge that there will be inherent responder
bias in the returned questionnaires measuring disease-related
quality of life and disease control and activation. However,
health care usage was obtained from GP records and was
therefore not subject to bias.
Experiences of the project have shown that diagnoses of asthma
remain difficult to manage in primary care. A total of 14% of
our care cohort was rediagnosed with asthma and 10% with
asthma-COPD overlap. Similarly, with the case-finding cohort,
the predominant diagnosis was unrecognized asthma. Given the
drive to recognize the complexity of airways disease with
targeting of “treatable traits” [12], there is a need to improve
recognition of these patients, especially those with evidence of
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significant triggers or eosinophilic airway inflammation. In a
similar community respiratory clinic, Hasset et al [13] found
that one-third of the patients referred for likely COPD were
misdiagnosed, and in our clinic, this value was one-quarter.
Overall, the case-finding cohort uncovered an undiagnosed
airways disease in 83% of those assessed. Of the 38 identified,
16 were receiving inhaled therapy without a formal diagnosis.
Of these, two had their inhalers stopped where no treatable
diagnosis was established.
The MISSION project proactively identified comorbidity
through the use of validated screening questionnaires (HADS,
Epworth, Nijmegen, Gastroesophageal Reflux Disease
Questionnaire) followed by a medical review. A total of 41%
patients screened positive for dysfunctional ventilation, although
equal distribution was seen between the case and care cohorts.
This suggests that, in this group, underrecognition of
dysfunctional ventilation was not a significant barrier to
recognition of the cause of breathlessness. Anxiety and
depression was found in 29% of the patients, with a greater
prevalence in the case-finding cohort. A review by Livermore
et al [14] revealed that the prevalence of panic disorder in COPD
is not well defined, with evidence showing a range of 6%-67%;
however, there are consistent reports that the presence of anxiety
symptoms with COPD predicts an increased duration and
frequency of hospital admission. A recent report by the Kings
Fund [15] reveals that, independent of the severity of COPD,
comorbid anxiety and depression worsen health outcomes and
breathlessness with a greater impact in those of lower
socioeconomic status. Furthermore, poor mental health will
result in lower adherence to using prescribed medications. Both
of the abovementioned works highlight the importance of
screening and treatment efforts, but suggest that, even with
proactive screening, we may have underrecognized cases and
further work may be needed.
The additional comorbidities found at the severe clinic highlight
the presence of a complex group of patients where unrecognized
comorbidity may be a significant contributor to the burden of
symptoms and subsequently the drive to health care
consumption. These patients were sought proactively, suggesting
that it may have been many months, if not years, before these
conditions were recognized and addressed.
Unscheduled care usage, defined as unplanned GP visits, calls
to the GP out-of-hours service, or hospital attendances were
reduced for both sectors. However, the biggest impact was in
the reduction in exacerbations and GP attendances. The numbers
of hospital attendances and admissions in the 12 months before
the MISSION clinic were low in this cohort, but it is noteworthy
that one ED visit costs almost twice that of an unscheduled GP
visit; therefore, fewer reductions are needed to lead to savings
in the health economy. A review by Roland and Abel [16] found
that the best strategy of targeting patients at risk of admission
yields greater savings than those already in a pattern of repeat
admission, supporting the proactive case identification favored
by MISSION. Sensitivity analyses support the significant
benefits in reduction of hospital attendances or admissions, if
patients are prioritized for this clinic on the basis of such
episodes.
Sustained improvements were seen in the SGRQ, although these
were more evident among the case cohort. This demonstrates
value in case finding, where addressing symptom drivers with
the patient can allow for effective treatment and
self-management. Significant reductions were seen in the CAT
scores at 6 months, supporting this model as an effective method
for achieving disease control in addition to the quality of life.
Patient activation and confidence in self-management were
shown to improve and to be sustainable. Over the longer term,
this has the potential to reduce cost to the health system, improve
patient empowerment, and ultimately make them active
participants in their health care [17].
MISSION COPD sought to deliver gold-standard comprehensive
integrated COPD care that met the needs of this complex group
of patients. This goal is not new, but a recent Cochrane review
[4] did not find evidence of another project that met all of their
recommended inclusions for a gold-standard service. Through
this project, we have shown that the model is feasible and cost
saving. More importantly, it delivered improvements in disease
control, quality of life, and confidence of patients. The
MISSION team will now test this model on larger scales to
demonstrate the replicability of these results.
Cost savings have been demonstrated across all domains. No
single measure reached statistical significance when considering
the whole cohort, although it is noteworthy that the study was
designed as an improvement program; therefore, sample sizes
were defined by the delivery design and not powered for
significance. When cost measures were compared for patients
who had attended secondary care through ED or were admitted
for the following episodes before the clinic, a statistically
significant cost reduction was seen. Cost savings have been
calculated using each patient as their own control, which we
believe has rigor, as no other national or local initiative was
delivered to this population. Thus, there were no other possible
influences on participant outcomes. The calculation of
equivalent diagnostic and follow-up visits to primary or
secondary care providers also demonstrate the cost efficiencies
that can be made by delivering these one-stop or two-stop clinics
rather than the multi-visit, multisector model that currently
exists. We believe this shows health economic benefits, both
in its current manifestation and in case the inclusion criteria
were narrowed further to include only those presenting to or
admitted to the hospital.
The MISSION COPD pilot was a small-scale project testing
the feasibility and acceptability of the model. To demonstrate
the significant impact on delivery, particularly in realizing
pounds-in-pockets savings, the model needs to be tested to scale.
Outcomes were only measured up to 6 months. To ensure that
improvements are sustainable beyond the initial follow-up
period, further 12-month data should also be sought in scaled
tests to allow for greater generalizability.
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